Carisbamate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Carisbamate
- Accession Number
- DB12338
- Description
Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Carisbamate (DB12338)
- Weight
- Average: 215.63
Monoisotopic: 215.0349209 - Chemical Formula
- C9H10ClNO3
- Synonyms
- Not Available
- External IDs
- JNJ-10234094
- RWJ-333369-000
- YKP-509
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Carisbamate. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Carisbamate. Aclidinium Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Carisbamate. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Carisbamate. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Carisbamate. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Carisbamate. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Carisbamate. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Carisbamate. Alverine The risk or severity of adverse effects can be increased when Alverine is combined with Carisbamate. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- ATC Codes
- N03AX19 — Carisbamate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Chlorobenzenes
- Alternative Parents
- Aryl chlorides / Carbamate esters / Secondary alcohols / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
- Substituents
- Alcohol / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Carbamic acid ester / Carbonyl group / Chlorobenzene / Hydrocarbon derivative / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- P7725I9V3Z
- CAS number
- 194085-75-1
- InChI Key
- OLBWFRRUHYQABZ-MRVPVSSYSA-N
- InChI
- InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
- IUPAC Name
- (2S)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate
- SMILES
- NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl
References
- General References
- Not Available
- External Links
- PubChem Compound
- 6918474
- PubChem Substance
- 347828597
- ChemSpider
- 5293671
- ChEBI
- 135966
- ChEMBL
- CHEMBL2087003
- ZINC
- ZINC000030691363
- Wikipedia
- Carisbamate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Complex Partial Seizures / Epilepsies / Epilepsy, Complex Partial / Epilepsy, Localization Related 1 3 Completed Treatment Epilepsy, Complex Partial / Epilepsy, Partial, Motor / Epilepsy, Simple Partial / Focal Motor Epilepsy 2 3 Terminated Treatment Epilepsies / Seizures 1 2 Completed Treatment Diabetic Mononeuropathy / Diabetic Neuropathy, Painful / Diabetic Polyneuropathy / Neuralgia, Diabetic 1 2 Completed Treatment Diabetic Neuropathies 1 2 Completed Treatment Essential Tremor, Movement Disorders 1 2 Completed Treatment Herpes Zoster / Neuralgia / Postherpetic Neuralgia 1 1 Active Not Recruiting Treatment Healthy Volunteers 1 1 Recruiting Basic Science Lennox Gastaut Syndrome / Lennox-Gastaut Syndrome (LGS) 2 1, 2 Unknown Status Other Alcohol Abuse / Alcohol Dependence / Substance Abuse 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.15 mg/mL ALOGPS logP 0.94 ALOGPS logP 1.29 ChemAxon logS -2 ALOGPS pKa (Strongest Acidic) 13.43 ChemAxon pKa (Strongest Basic) -3.5 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 72.55 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 51.47 m3·mol-1 ChemAxon Polarizability 20.38 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 16:00 / Updated on June 12, 2020 10:53